Author: Zacks Small Cap Research

1919293949597930 / 967 POSTS
By John Vandermosten, CFA NASDAQ:TTNP Titan Partners with Molteni for EU CommercializationTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced on November 28th an agreement with private Italian company L. Molteni & C. dei F.lli Alitti Società di Eserc ...
By David Bautz, PhDTSX:ATE.VAntibe Therapeutics Inc. (TSX:ATE.V) is a Canadian biotechnology company developing treatments for pain, inflammation, and regenerative medicine. The company’s lead compound, ATB-346, is an improved non-steroidal anti-infl ...
NASDAQ:RXII Immunotherapy is one of the most exciting areas in biotechnology today.  It holds the promise of improved efficacy and greater safety by augmenting and enhancing the body’s innate ability to fight disease, seek out damaged cells an ...
By Brian Marckx, CFA NASDAQ:CEMI MODEL ADJUSTMENTS FOR $8.5M FIOCRUZ ORDER, UNICEF RFP AWARD (UP TO $4.9M)New $8.5M DPP HIV, Leishmania Order From Brazil Prompts Upward Revision to Estimated 2018 Revenue…Earlier this week (Dec 5th) Chembio (NASDAQ:CE ...
NASDAQ:CKPT Checkpoint Therapeutics (NASDAQ:CKPT) boasts an impressive portfolio of immuno-oncology and anti-cancer agents that have the potential for approvals as both mono- and combination therapies.  Checkpoint has six compounds in devel ...
By Lisa Thompson NASDAQ:PIXY Last night, ShiftPixy (NASDAQ:PIXY) filed a Form 12b-25 Notification of Late Filing, for its 10K for the year ending August 31, 2017. The company now has 15 days to finish its audit, (which it believes will be issued with ...
1919293949597930 / 967 POSTS